Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [31] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [32] Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.
    Shagisultanova, Elena
    Chalasani, Pavani
    Brown-Glaberman, Ursa Abigail
    Gradishar, William John
    Brenner, Andrew Jacob
    Stopeck, Alison
    Gao, Dexiang
    McSpadden, Tessa
    Kabos, Peter
    Borges, Virginia F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [34] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
  • [35] Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
    Hope S. Rugo
    Peter Kabos
    J. Thad Beck
    Guy Jerusalem
    Hans Wildiers
    Elena Sevillano
    Luis Paz-Ares
    Michael J. Chisamore
    Sonya C. Chapman
    Anwar M. Hossain
    Yanyun Chen
    Sara M. Tolaney
    npj Breast Cancer, 8
  • [36] Evolving perspectives on the treatment of HR+/HER2+metastatic breast cancer
    Pegram, Mark
    Pietras, Richard
    Dang, Chau T.
    Murthy, Rashmi
    Bachelot, Thomas
    Janni, Wolfgang
    Sharma, Priyanka
    Hamilton, Erika
    Saura, Cristina
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [38] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [39] Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2-metastatic breast cancer in the United States
    Goyal, Ravi K.
    Cuyun Carter, Gebra
    Nagar, Saurabh P.
    Nash Smyth, Emily
    Price, Gregory L.
    Parikh, Rohan C.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 699 - 710
  • [40] Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2-metastatic breast cancer
    Goyal, Ravi K.
    Carter, Gebra Cuyun
    Nagar, Saurabh P.
    Smyth, Emily N.
    Price, Gregory L.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (10) : 1699 - 1710
12345